Adimab inks deals with Lilly, Genentech and HGS

Lebanon, NH-based Adimab has added some noteworthy players to its long list of partners trying out its antibody development technology. The 2010 Fierce 15 company announced today that Eli Lilly, Genentech, and Human Genome Sciences have all inked new collaboration deals. "As more companies develop therapeutic leads against the same validated disease targets, leading Pharma companies are actively seeking out technologies that give them a meaningful advantage and Adimab's deal flow speaks for itself," said Tillman Gerngross, Adimab's CEO and co-founder. "In this highly competitive environment, having access to the best technology becomes essential, not optional. Our ability to provide high quality leads in a matter of months is driving the demand for our technology." Adimab release

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.